Virovet
ViroVet is a pioneering company dedicated to developing disruptive and innovative technologies for controlling viral diseases in livestock. Their pipeline includes antiviral drugs for respiratory diseases and innovative vaccines, utilizing unique technology platforms to produce cost-effective, tailor-made vaccines that do not require cold chain storage.
Industries
Nr. of Employees
small (1-50)
Virovet
Ambachtenlaan 1, 3001 Leuven, Belgium, BE 0634 891 328
Products
Plasmid-launched live attenuated virus vaccines for livestock
Vaccine candidates generated from plasmid DNA that launch attenuated viruses in vivo, designed to be tailor-made for target pathogens and species while minimizing safety concerns.
Antiviral therapeutics for livestock viral diseases
Fast-acting antiviral drug candidates developed to treat respiratory and other viral diseases in cattle and swine, with applications to endemic and epizootic threats.
Plasmid-launched live attenuated virus vaccines for livestock
Vaccine candidates generated from plasmid DNA that launch attenuated viruses in vivo, designed to be tailor-made for target pathogens and species while minimizing safety concerns.
Antiviral therapeutics for livestock viral diseases
Fast-acting antiviral drug candidates developed to treat respiratory and other viral diseases in cattle and swine, with applications to endemic and epizootic threats.
Services
Partner-based research programs with academic and research institutes to co-develop vaccines and antivirals, including joint validation and shared development activities.
Provision of in vivo efficacy studies, challenge testing in relevant animal species, and temporary laboratory support for outbreak-related sample testing.
Partner-based research programs with academic and research institutes to co-develop vaccines and antivirals, including joint validation and shared development activities.
Provision of in vivo efficacy studies, challenge testing in relevant animal species, and temporary laboratory support for outbreak-related sample testing.
Expertise Areas
- Vaccine platform development
- Antiviral drug discovery for veterinary applications
- Preclinical animal-model efficacy testing
- Veterinary vaccine manufacturing and scale-up
Key Technologies
- Plasmid-launched live attenuated vaccine technology
- Modified live virus (MLV) vaccine production
- Plasmid DNA vaccine strategies
- Small-molecule antiviral discovery
News & Updates
Apr 22, 2025. The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meetings of their kind across the globe since 2000.
Jun 24, 2025. VetHealth Global is North America’s premier animal health and nutrition business conference. It will take place in Charlottetown, Prince Edward Island.
May 8, 2025. The Belgian life sciences community will attend this annual conference in Antwerp, Belgium.
May 12, 2025. The event will be organized in Bruges, Belgium, with flanders.bio as one of the hosts.
Aug 2023 - ViroVet achieved groundbreaking results with an antiviral drug against BVD.
Jun 2022 - The company raised close to 20 million euros since its start.
Apr 22, 2025. The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meetings of their kind across the globe since 2000.
Jun 24, 2025. VetHealth Global is North America’s premier animal health and nutrition business conference. It will take place in Charlottetown, Prince Edward Island.
May 8, 2025. The Belgian life sciences community will attend this annual conference in Antwerp, Belgium.
May 12, 2025. The event will be organized in Bruges, Belgium, with flanders.bio as one of the hosts.
Aug 2023 - ViroVet achieved groundbreaking results with an antiviral drug against BVD.
Jun 2022 - The company raised close to 20 million euros since its start.